{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:06:49Z","timestamp":1783663609987,"version":"3.55.0"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>As one of the most malignant tumors worldwide, lung cancer, fueled by metastasis, has shown rising mortality rates. However, effective clinical strategies aimed at preventing metastasis are lacking owing to its dynamic multi-step, complicated, and progressive nature. Immunotherapy has shown promise in treating cancer metastasis by reversing the immunosuppressive network of the tumor microenvironment. However, drug resistance inevitably develops due to inadequate delivery of immunostimulants and an uncontrolled immune response. Consequently, adverse effects occur, such as autoimmunity, from the non-specific immune activation and non-specific inflammation in off-target organs. Nanocarriers that improve drug solubility, permeability, stability, bioavailability, as well as sustained, controlled, and targeted delivery can effectively overcome drug resistance and enhance the therapeutic effect while reducing adverse effects. In particular, nanomedicine-based immunotherapy can be utilized to target tumor metastasis, presenting a promising therapeutic strategy for lung cancer. Nanotechnology strategies that boost the immunotherapy effect are classified based on the metastatic cascade related to the tumor immune microenvironment; the breaking away of primary tumors, circulating tumor cell dissemination, and premetastatic niche formation cause distant secondary site colonization. In this review, we focus on the opportunities and challenges of integrating immunotherapy with nanoparticle formulation to establish nanotechnology-based immunotherapy by modulating the tumor microenvironment for preclinical and clinical applications in the management of patients with metastatic lung cancer. We also discuss prospects for the emerging field and the clinical translation potential of these techniques.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002525","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T02:54:44Z","timestamp":1689303284000},"page":"2787-2801","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis"],"prefix":"10.1097","volume":"136","author":[{"given":"Lingling","family":"Zhu","sequence":"first","affiliation":[{"name":"Lung Cancer Center, Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, College of Polymer Science and Engineering, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[{"name":"Out-patient Department, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, College of Polymer Science and Engineering, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Lung Cancer Center, Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Lung Cancer Center, Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, College of Polymer Science and Engineering, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Lung Cancer Center, Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.trecan.2020.05.001","article-title":"Nanotherapeutics for antimetastatic treatment","volume":"6","author":"Yang","year":"2020","journal-title":"Trends Cancer"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massague","year":"2016","journal-title":"Nature"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","article-title":"The lung microenvironment: an important regulator of tumour growth and metastasis","volume":"19","author":"Altorki","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.3390\/cancers13225621","article-title":"The role of the innate immune system in cancer dormancy and relapse","volume":"13","author":"Chernosky","year":"2021","journal-title":"Cancers"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejmech.2019.03.053","article-title":"The peculiarities of cancer cell metabolism: a route to metastasization and a target for therapy","volume":"171","author":"Carvalho","year":"2019","journal-title":"Eur J Med Chem"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","article-title":"Circulating and disseminated tumour cells \u2013 mechanisms of immune surveillance and escape","volume":"14","author":"Mohme","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"e2103836","DOI":"10.1002\/advs.202103836","article-title":"Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy","volume":"9","author":"Peng","year":"2022","journal-title":"Adv Sci"},{"key":"R9-20250602","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","author":"Liu","year":"2022","journal-title":"Chin Chem Lett"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.apsb.2020.07.013","article-title":"The progress and perspective of nanoparticle-enabled tumor metastasis treatment","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"e1904156","DOI":"10.1002\/adma.201904156","article-title":"Nanomedicine-based immunotherapy for the treatment of cancer metastasis","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv Mater"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.011","article-title":"Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer","volume":"123","author":"Grossi","year":"2019","journal-title":"Eur J Cancer"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"e2002163","DOI":"10.1002\/adhm.202002163","article-title":"Nanotechnology-based strategies to evaluate and counteract cancer metastasis and neoangiogenesis","volume":"10","author":"Sen","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","article-title":"Roadmap and strategy for overcoming infusion reactions to nanomedicines","volume":"13","author":"Szebeni","year":"2018","journal-title":"Nat Nanotechnol"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"AAPS J"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"188703","DOI":"10.1016\/j.bbcan.2022.188703","article-title":"Targeting nanoparticles to malignant tumors","volume":"1877","author":"Sharma","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12951-020-00741-z","article-title":"Emerging nanomedicines for effective breast cancer immunotherapy","volume":"18","author":"Bahreyni","year":"2020","journal-title":"J Nanobiotechnology"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ctrv.2013.10.001","article-title":"The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets","volume":"40","author":"Wood","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1039\/C6CS00458J","article-title":"Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy","volume":"45","author":"Liang","year":"2016","journal-title":"Chem Soc Rev"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1158\/2326-6066.CIR-20-0637","article-title":"Longitudinal immune profiling reveals unique myeloid and T-cell phenotypes associated with spontaneous immunoediting in a prostate tumor model","volume":"9","author":"Ager","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrc3180","article-title":"Treating metastatic cancer with nanotechnology","volume":"12","author":"Schroeder","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","article-title":"Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC","volume":"20","author":"Chen","year":"2021","journal-title":"Mol Cancer"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1021\/acs.molpharmaceut.1c00962","article-title":"Cationic nanoparticulate system for codelivery of microRNA-424 and podophyllotoxin as a multimodal anticancer therapy","volume":"19","author":"Wang","year":"2022","journal-title":"Mol Pharm"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.actbio.2021.08.013","article-title":"Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1\/PD-L1 inhibitors than the parental drug","volume":"135","author":"Shen","year":"2021","journal-title":"Acta Biomater"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1039\/D0BM01191F","article-title":"Dual polymeric prodrug co-assembled nanoparticles with precise ratiometric co-delivery of cisplatin and metformin for lung cancer chemoimmunotherapy","volume":"8","author":"Yang","year":"2020","journal-title":"Biomater Sci"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1021\/acsnano.1c09391","article-title":"Self-assembly of podophyllotoxin-loaded lipid bilayer nanoparticles for highly effective chemotherapy and immunotherapy via downregulation of programmed cell death ligand 1 production","volume":"16","author":"Wang","year":"2022","journal-title":"ACS Nano"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"eaaz9240","DOI":"10.1126\/sciadv.aaz9240","article-title":"Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy","volume":"6","author":"Li","year":"2020","journal-title":"Sci Adv"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2147\/IJN.S285999","article-title":"Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors","volume":"16","author":"Qi","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"R33-20250602","first-page":"2158","article-title":"Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy","volume":"6","author":"Huang","year":"2021","journal-title":"Bioact Mater"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"eaaz6606","DOI":"10.1126\/scitranslmed.aaz6606","article-title":"Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy","volume":"12","author":"Lu","year":"2020","journal-title":"Sci Transl Med"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"832725","DOI":"10.3389\/fphar.2022.832725","article-title":"Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer","volume":"13","author":"Feng","year":"2022","journal-title":"Front Pharmacol"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00432-021-03879-x","article-title":"Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer","volume":"148","author":"Yu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol Cancer"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","article-title":"Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function","volume":"81","author":"La Fleur","year":"2021","journal-title":"Cancer Res"},{"key":"R39-20250602","doi-asserted-by":"crossref","first-page":"24144","DOI":"10.1021\/acsami.2c03839","article-title":"Polyaniline-based glyco-condensation on Au nanoparticles enhances immunotherapy in lung cancer","volume":"14","author":"Su","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"R40-20250602","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","article-title":"Immunotherapeutic effects of intratumoral nanoplexed poly I:C","volume":"7","author":"Aznar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3389\/fimmu.2018.02520","article-title":"Both type I and type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation","volume":"9","author":"Muller","year":"2018","journal-title":"Front Immunol"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4049\/jimmunol.0712671","article-title":"Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells","volume":"182","author":"Dumitriu","year":"2009","journal-title":"J Immunol"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.7150\/thno.34429","article-title":"Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles","volume":"9","author":"Da Silva","year":"2019","journal-title":"Theranostics"},{"key":"R45-20250602","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.nano.2021.102415","article-title":"Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7\/8 agonist in lung cancer model","volume":"37","author":"Koh","year":"2021","journal-title":"Nanomedicine"},{"key":"R46-20250602","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acsnano.0c09681","article-title":"Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy","volume":"15","author":"Hu","year":"2021","journal-title":"ACS Nano"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41590-020-0745-y","article-title":"ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung","volume":"21","author":"Schuijs","year":"2020","journal-title":"Nat Immunol"},{"key":"R48-20250602","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14712598.2020.1688298","article-title":"NK cell-based therapeutics for lung cancer","volume":"20","author":"Pockley","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R49-20250602","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1039\/C8BM00588E","article-title":"Magnetic delivery of Fe3O4@polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment","volume":"6","author":"Wu","year":"2018","journal-title":"Biomater Sci"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.009","article-title":"Cancer-associated fibroblasts in non-small cell lung cancer: recent advances and future perspectives","volume":"514","author":"Zhang","year":"2021","journal-title":"Cancer Lett"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"14381","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils dominate the immune cell composition in non-small cell lung cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat Commun"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-017-0742-4","article-title":"Factors involved in cancer metastasis: a better understanding to \u201cseed and soil\u201d hypothesis","volume":"16","author":"Liu","year":"2017","journal-title":"Mol Cancer"},{"key":"R53-20250602","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R54-20250602","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-1141-9","article-title":"Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy","volume":"19","author":"Zhong","year":"2020","journal-title":"Mol Cancer"},{"key":"R55-20250602","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.21037\/jtd-20-1026A","article-title":"Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients using peptide-functionalized magnetic nanoparticles","volume":"12","author":"Liang","year":"2020","journal-title":"J Thorac Dis"},{"key":"R56-20250602","doi-asserted-by":"crossref","first-page":"e1801231","DOI":"10.1002\/adhm.201801231","article-title":"A microwell-assisted multiaptamer immunomagnetic platform for capture and genetic analysis of circulating tumor cells","volume":"7","author":"Dong","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"R57-20250602","doi-asserted-by":"crossref","first-page":"111542","DOI":"10.1016\/j.colsurfb.2020.111542","article-title":"Evaluation of a new magnetic bead as an integrated platform for systematic CTC recognition, capture and clinical analysis","volume":"199","author":"Lu","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"key":"R58-20250602","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"R59-20250602","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R60-20250602","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","article-title":"Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis","volume":"184","author":"Kaczanowska","year":"2021","journal-title":"Cell"},{"key":"R61-20250602","first-page":"739","volume":"39","author":"Hsu","year":"2020","journal-title":"Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer Oncogene"},{"key":"R62-20250602","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccell.2016.06.021","article-title":"Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"R63-20250602","doi-asserted-by":"crossref","first-page":"111478","DOI":"10.1016\/j.bios.2019.111478","article-title":"Nanoplasmonics-enhanced label-free imaging of endothelial cell monolayer integrity","volume":"141","author":"Banville","year":"2019","journal-title":"Biosens Bioelectron"},{"key":"R64-20250602","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/cancers14010083","article-title":"Physical forces and transient nuclear envelope rupture during metastasis: the key for success?","volume":"14","author":"Gauthier","year":"2021","journal-title":"Cancers"},{"key":"R65-20250602","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.apsb.2020.11.024","article-title":"Emerging nanomedicine-based therapeutics for hematogenous metastatic cascade inhibition: interfering with the crosstalk between \u201cseed and soil\u201d","volume":"11","author":"Wu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"R66-20250602","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.trecan.2022.03.002","article-title":"Ecology and evolution of dormant metastasis","volume":"8","author":"Blasco","year":"2022","journal-title":"Trends Cancer"},{"key":"R67-20250602","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1158\/0008-5472.CAN-08-3691","article-title":"Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes","volume":"69","author":"Long","year":"2009","journal-title":"Cancer Res"},{"key":"R68-20250602","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R69-20250602","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2018.12.028","article-title":"Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy","volume":"85","author":"Huang","year":"2019","journal-title":"Acta Biomater"},{"key":"R70-20250602","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"R71-20250602","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.molcel.2019.05.006","article-title":"SLC19A1 is an importer of the immunotransmitter cGAMP","volume":"75","author":"Ritchie","year":"2019","journal-title":"Mol Cell"},{"key":"R72-20250602","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.3390\/molecules24224192","article-title":"ENPP1, an old enzyme with new functions, and small molecule inhibitors \u2013 a STING in the Tale of ENPP1","volume":"24","author":"Onyedibe","year":"2019","journal-title":"Molecules"},{"key":"R73-20250602","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R74-20250602","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"R75-20250602","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1021\/acs.nanolett.8b00689","article-title":"Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b","volume":"18","author":"Parayath","year":"2018","journal-title":"Nano Lett"},{"key":"R76-20250602","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10555-016-9618-0","article-title":"Progression and metastasis of lung cancer","volume":"35","author":"Popper","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"R77-20250602","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/08977194.2011.624517","article-title":"A novel vaccine delivery system: biodegradable nanoparticles in thermosensitive hydrogel","volume":"29","author":"Wu","year":"2011","journal-title":"Growth Factors"},{"key":"R78-20250602","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1021\/acsnano.0c02207","article-title":"Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer","volume":"14","author":"Perry","year":"2020","journal-title":"ACS Nano"},{"key":"R79-20250602","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/aps.2009.44","article-title":"Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface","volume":"30","author":"Ren","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"R80-20250602","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1039\/D1NR06518A","article-title":"Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer","volume":"14","author":"Wang","year":"2022","journal-title":"Nanoscale"},{"key":"R81-20250602","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijrobp.2021.06.041","article-title":"Radiation therapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects","volume":"111","author":"Hu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R82-20250602","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R83-20250602","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/molecules26040785","article-title":"Recent advances in nanotechnology for the treatment of melanoma","volume":"26","author":"Cassano","year":"2021","journal-title":"Molecules"},{"key":"R84-20250602","doi-asserted-by":"crossref","first-page":"e2100078","DOI":"10.1002\/adhm.202100078","article-title":"Nanotechnology: breaking the current treatment limits of lung cancer","volume":"10","author":"Li","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"R85-20250602","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R86-20250602","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R87-20250602","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"R88-20250602","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"R89-20250602","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"R90-20250602","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"R91-20250602","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"R92-20250602","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R93-20250602","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"R94-20250602","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"R95-20250602","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"R96-20250602","doi-asserted-by":"crossref","first-page":"802467","DOI":"10.3389\/fonc.2022.802467","article-title":"Efficacy and safety of low-dose nab-paclitaxel plus tislelizumab in elderly patients with previously treated metastatic non-small cell lung cancer","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"R97-20250602","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","article-title":"A phase II trial of cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer","volume":"74","author":"Ahn","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"R98-20250602","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:00:53Z","timestamp":1748905253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":98,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002525","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}